- Home
- AIIO vs CPHI Comparison
AIIO vs CPHI Comparison
Compare AIIO & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIO | CPHI |
|---|---|---|
| Founded | N/A | N/A |
| Country | United Arab Emirates | China |
| Employees | 68 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 26.3M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | AIIO | CPHI |
|---|---|---|
| Price | $0.70 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 8.8K |
| Earning Date | 05-02-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $0.50 |
| 52 Week High | $2.82 | $2.60 |
Technical Indicators
Market Signals| Indicator | AIIO | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 52.98 |
| Support Level | $0.17 | $0.53 |
| Resistance Level | $0.73 | $0.66 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 56.57 | 87.31 |
Price Performance
Historical ComparisonAbout AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.